|
289 Companies |
|
370 Products |
|
370 Products |
|
178 Mechanisms of Action |
|
18 Trials |
|
3676 News |
|
| «12345678910111213...7778» |
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=11, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=23 --> 11
- | Torisel (temsirolimus) / Pfizer
Trial completion: Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jun 3, 2018
P1/2, N=115, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=23 --> 11 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
Trial completion: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jun 3, 2018
P2, N=116, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma (clinicaltrials.gov) - Jun 3, 2018
P2, N=20, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| SF1126 / SignalRx
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: SF1126 for Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Jun 3, 2018
P1, N=4, Terminated, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Active, not recruiting --> Completed N=28 --> 4 | Trial completion date: Jun 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Low patient accrual
- | Trial completion, Enrollment change, Trial completion date: PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy? (clinicaltrials.gov) - Jun 2, 2018
P1, N=90, Completed, Sponsor: University Ghent
N=28 --> 4 | Trial completion date: Jun 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Low patient accrual Recruiting --> Completed | N=20 --> 90 | Trial completion date: Oct 2015 --> Mar 2018
- || Avastin (bevacizumab) / Roche
Trial completion: Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Jun 2, 2018
P1, N=13, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed | N=20 --> 90 | Trial completion date: Oct 2015 --> Mar 2018 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: CINDERELLA: Carbon Ion Radiotherapy for Recurrent Gliomas (clinicaltrials.gov) - Jun 2, 2018
P1/2, N=56, Completed, Sponsor: University Hospital Heidelberg
Active, not recruiting --> Completed Recruiting --> Completed | N=436 --> 56
- ||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Trial completion: A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Jun 2, 2018
P1, N=54, Completed, Sponsor: Tocagen Inc.
Recruiting --> Completed | N=436 --> 56 Active, not recruiting --> Completed
- ||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Trial completion: Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor (clinicaltrials.gov) - Jun 1, 2018
P1, N=58, Completed, Sponsor: Tocagen Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tabrecta (capmatinib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Trial termination: Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jun 1, 2018
P1/2, N=43, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Completed --> Terminated
- || vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Trial completion: Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor (clinicaltrials.gov) - Jun 1, 2018
P1, N=17, Completed, Sponsor: Tocagen Inc.
Completed --> Terminated Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap
Enrollment change: Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma (clinicaltrials.gov) - May 3, 2018
P2, N=52, Completed, Sponsor: John P. Fruehauf
Active, not recruiting --> Completed N=82 --> 52
- | hydroxychloroquine / Generic mfg.
Trial completion: A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) (clinicaltrials.gov) - May 3, 2018
P2, N=54, Completed, Sponsor: University College, London
N=82 --> 52 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma (clinicaltrials.gov) - May 2, 2018
P1, N=71, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Phase classification, Enrollment change: A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - May 2, 2018
P1, N=25, Terminated, Sponsor: Milton S. Hershey Medical Center
Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019 Phase classification: P1/2 --> P1 | N=10 --> 25
- | Trial completion: Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (clinicaltrials.gov) - May 2, 2018
P2, N=51, Completed, Sponsor: Craig L Slingluff, Jr
Phase classification: P1/2 --> P1 | N=10 --> 25 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion, Trial completion date: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - May 2, 2018
P1, N=27, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017
- ||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Apr 26, 2018
P2, N=53, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017 Terminated --> Completed
- | temozolomide / Generic mfg.
Trial completion: Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Apr 25, 2018
P2, N=32, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Terminated --> Completed Active, not recruiting --> Completed
- | Nplate (romiplostim) / Amgen
Enrollment change, Trial termination: PLATUM: Prevention of Thrombocytopenia in Glioblastoma Patients (clinicaltrials.gov) - Apr 25, 2018
P2, N=20, Terminated, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed N=35 --> 20 | Recruiting --> Terminated; Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.
- | Beleodaq (belinostat) / Aurobindo, Assertio
Trial completion date: A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers (clinicaltrials.gov) - Apr 24, 2018
P1, N=28, Completed, Sponsor: National Cancer Institute (NCI)
N=35 --> 20 | Recruiting --> Terminated; Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients. Trial completion date: Jun 2017 --> Apr 2018
- | SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion, Enrollment change: Sorafenib and Radioembolization With Sir-Spheres (clinicaltrials.gov) - Apr 23, 2018
P1, N=11, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
Trial completion date: Jun 2017 --> Apr 2018 Active, not recruiting --> Completed | N=24 --> 11
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=24 --> 11 Active, not recruiting --> Completed
- | Inlyta (axitinib) / Pfizer
Trial completion, Trial completion date: A Study of Axitinib in Advanced Carcinoid Tumors (clinicaltrials.gov) - Apr 18, 2018
P2, N=30, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Feb 2018
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial termination: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Apr 18, 2018
P2, N=53, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Feb 2018 Recruiting --> Terminated; The applicant decided to close the study
- | Trial completion date, Trial primary completion date, IO biomarker, Metastases: Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma (clinicaltrials.gov) - Apr 18, 2018
P1, N=24, Suspended, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Terminated; The applicant decided to close the study Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018
- | Torisel (temsirolimus) / Pfizer
Phase classification: A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018 Phase classification: P=N/A --> P1
- | bafetinib (INNO-406) / LadRx
Phase classification: Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases (clinicaltrials.gov) - Apr 17, 2018
P1, N=7, Completed, Sponsor: City of Hope Medical Center
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P1
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date: A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma (clinicaltrials.gov) - Apr 13, 2018
P2, N=3, Completed, Sponsor: Emory University
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion date: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 10, 2018
P1, N=26, Active, not recruiting, Sponsor: Altor BioScience
Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018 Trial completion date: Apr 2018 --> Jul 2018
- belapectin (GR-MD-02) / Galectin Therap, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 4, 2018
P1, N=8, Active, not recruiting, Sponsor: Providence Health & Services
Trial completion date: Apr 2018 --> Jul 2018 Recruiting --> Active, not recruiting | N=22 --> 8 | Trial primary completion date: Mar 2018 --> Dec 2018
- | Proleukin (aldesleukin) / Iovance Biotherap
Biomarker, Trial completion, Phase classification: Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma (clinicaltrials.gov) - Apr 2, 2018
P, N=15, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | N=22 --> 8 | Trial primary completion date: Mar 2018 --> Dec 2018 Active, not recruiting --> Completed | Phase classification: PN/A --> P
- | temozolomide / Generic mfg., disulfiram / Generic mfg.
Trial completion date: Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide (clinicaltrials.gov) - Apr 2, 2018
P1, N=21, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | Phase classification: PN/A --> P Trial completion date: Mar 2018 --> Jun 2018
- | Phase classification: SAFE-MILND: Minimally Invasive Groin Dissection for Melanoma (clinicaltrials.gov) - Mar 23, 2018
P=N/A, N=88, Completed, Sponsor: Mayo Clinic
Trial completion date: Mar 2018 --> Jun 2018 Phase classification: P1 --> P=N/A
- | ITC-6146RO / IntoCell
Phase classification: Second Echelon Node Study With Methylene Blue (clinicaltrials.gov) - Mar 23, 2018
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
Phase classification: P1 --> P=N/A Phase classification: P1 --> P=N/A
- | ITC-6146RO / IntoCell
Trial completion, Trial completion date: Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery (clinicaltrials.gov) - Mar 22, 2018
P=N/A, N=30, Completed, Sponsor: Mayo Clinic
Phase classification: P1 --> P=N/A Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2017
- || Trial completion date, Trial primary completion date: MMS-TM: Validation of MMS Test for Cancer Monitoring (clinicaltrials.gov) - Mar 21, 2018
P=N/A, N=100, Recruiting, Sponsor: MedInnovation GmbH
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2017 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment closed: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Mar 16, 2018
P1/2, N=38, Active, not recruiting, Sponsor: Mohammed M Milhem
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- || buparlisib (AN2025) / Adlai Nortye
Trial completion date: Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma (clinicaltrials.gov) - Mar 15, 2018
P2, N=65, Active, not recruiting, Sponsor: Patrick Y. Wen, MD
Recruiting --> Active, not recruiting Trial completion date: Jan 2018 --> Aug 2018
- | Yervoy (ipilimumab) / BMS
Biomarker, Trial completion: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Mar 15, 2018
P1, N=30, Completed, Sponsor: Diwakar Davar
Trial completion date: Jan 2018 --> Aug 2018 Active, not recruiting --> Completed
- | Xalkori (crizotinib) / Pfizer
Enrollment closed: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 9, 2018
P1, N=36, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ITC-6146RO / IntoCell
Trial completion: 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours (clinicaltrials.gov) - Mar 9, 2018
P2, N=142, Completed, Sponsor: Arcispedale Santa Maria Nuova-IRCCS
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Xalkori (crizotinib) / Pfizer
Trial primary completion date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 7, 2018
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Trial primary completion date: Feb 2018 --> Mar 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion date: Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma (clinicaltrials.gov) - Mar 6, 2018
P1, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2018 --> Mar 2018 Trial completion date: Dec 2017 --> Dec 2018
- SNX-5422 / Esanex
Trial completion date, Trial primary completion date: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (clinicaltrials.gov) - Mar 3, 2018
P1, N=19, Active, not recruiting, Sponsor: Esanex Inc.
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Oct 2017 --> Mar 2018 | Trial primary completion date: Feb 2017 --> Mar 2017
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion date: Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Mar 3, 2018
P1, N=34, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Oct 2017 --> Mar 2018 | Trial primary completion date: Feb 2017 --> Mar 2017 Trial completion date: Feb 2019 --> Oct 2018
- Avastin (bevacizumab) / Roche
Trial completion date: Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Mar 3, 2018
P2, N=41, Active, not recruiting, Sponsor: Duke University
Trial completion date: Feb 2019 --> Oct 2018 Trial completion date: Jan 2017 --> Jan 2019
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=20, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2017 --> Jan 2019 Not yet recruiting --> Completed | Trial primary completion date: May 2015 --> Dec 2015
- Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial initiation date, Trial termination: Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Feb 27, 2018
P1, N=30, Terminated, Sponsor: Actelion
Not yet recruiting --> Completed | Trial primary completion date: May 2015 --> Dec 2015 Initiation date: Oct 2014 --> Jan 2015 | Completed --> Terminated; Sponsor decision due to low recruitment